Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6449
+0.00380.59%
Post-market: 0.6400-0.0049-0.76%19:59 EDT
Volume:9.49M
Turnover:6.07M
Market Cap:156.71M
PE:-0.86
High:0.6586
Open:0.6500
Low:0.6191
Close:0.6411
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.86
T/O Rate:4.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-15.08
PE(LYR):-0.36

Loading ...

NASDAQ Trade Halt Halt News Pending at 01:34 Pm

Reuters
·
Jul 25

Outlook Therapeutics Grants CEO, CFO Options at $1.43 Per Share

Reuters
·
Jul 24

Outlook Therapeutics Registers 17.3 Million Shares for Resale

MT Newswires Live
·
Jul 18

Outlook Therapeutics Shareholders Approve Increase in Authorized Common Shares to 600 Million

Reuters
·
Jul 17

Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8

Reuters
·
Jul 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)

TIPRANKS
·
Jun 30

Outlook Therapeutics Regains Nasdaq Compliance

MT Newswires Live
·
Jun 29

Outlook Therapeutics Regains NASDAQ Compliance After Shares Hold Above $1 Bid Threshold

Reuters
·
Jun 27

Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application

Dow Jones
·
Jun 16

BUZZ-Outlook Therapeutics rises after US FDA accepts to review eye disease treatment

Reuters
·
Jun 16

Outlook Therapeutics says FDA accepts resubmitted Lytentava BLA for wet AMD review

Reuters
·
Jun 16

Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for Ons-5010/Lytenava™ (Bevacizumab-Vikg) as a Treatment for Wet Amd

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Pdufa Target Action Date Set for July 29, 2026

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics - Initiates Pre-Launch Activities for Ons-5010/Lytenava

THOMSON REUTERS
·
Jun 16

Outlook Therapeutics director Yezan Munther Haddadin acquires 29,000 common shares for $24,145.40

Reuters
·
Jun 04

Outlook Therapeutics beneficial owner Ghiath M. Sukhtian reports $5 million common share purchase

Reuters
·
Jun 02

Outlook Therapeutics Resubmits Lytenava Biologics License Application to FDA

MT Newswires Live
·
Jun 01

Outlook Therapeutics resubmits FDA BLA for Lytneava in wet AMD

Reuters
·
Jun 01

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for Ons-5010/Lytenava™ (Bevacizumab-Vikg)

THOMSON REUTERS
·
Jun 01

Outlook Therapeutics - FDA Says No Additional Trials Required for Lytenava in Namd

THOMSON REUTERS
·
Jun 01